Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers

Part of paid clinical trials in La Jolla, California.

Sponsor
University of California, San Diego
Study ID
NCT05153304
Phase
PHASE1/PHASE2
Status
Withdrawn

Conditions

  • Cancer of Gastrointestinal Tract

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • personalized vaccine — BIOLOGICAL
    Vaccine will be constructed for each subject that express multiple candidate tumor-derived neoantigens.
  • Nivolumab — DRUG
    3mg/kg nivolumab will be administered intravenous (IV) infusion every 3 weeks for 4 doses. After 4 doses, 480 mg nivolumab will be administered intravenous (IV) infusion every 4 weeks.

Study Details

The purpose of this study is to determine if it is possible to make and safely administer a 'personalized' cancer vaccine for people diagnosed with an upper gastrointestinal tract cancer.

Key Dates

Start date
Jun 30, 2024
Status verified
Jun 2024
Primary completion
Jun 30, 2026
Completion
Jun 30, 2027

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: anti-PD1 and personalized vaccine

Primary Outcome Measure

Quantitative frequency of TCR [ Time Frame: 1 year ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, San DiegoLa JollaCalifornia92037-

Find similar trials in La Jolla, CA

By research site
University of California, San Diego· La Jolla, CA

Related Studies